Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate inquiry into Avandia safety puts GSK in the hot seat

This article was originally published in Scrip

Executive Summary

A US Senate inquiry into GlaxoSmithKline's Avandia (rosiglitazone) has found that the drug is needlessly hazardous and has accused the UK company of deliberately misleading physicians and the public over the safety profile of its much-beleaguered, once-blockbuster anti-diabetic.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC006945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel